SCHEMBL17444766

SCHEMBL17444766

O=C(NCc1ccc(F)cc1)C(=O)NCc1n[nH]c(=O)c2ccccc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.60
▸ POLB P06746 1/20 0.60
▸ PARP1 P09874 4/20 0.55
▸ BRD4 O60885 1/20 0.53
▸ TDP1 Q9NUW8 2/20 0.52
▸ LMNA P02545 2/20 0.51
▸ MAPT P10636 2/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ ALDH1A1 P00352 1/20 0.51
▸ GAA P10253 1/20 0.51
▸ THRB P10828 1/20 0.51
▸ HTT P42858 1/20 0.51
▸ RECQL P46063 1/20 0.51
▸ BLM P54132 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ HDAC1 Q13547 1/20 0.49
▸ ROCK2 O75116 1/20 0.49
▸ AR P10275 3/20 0.49
▸ GABRP O00591 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17444767 0.89 KDM4E (0.73) KDM4EPOLBPARP1BRD4TDP1
SCHEMBL17444769 0.80 KDM4E (0.57) KDM4EPOLBPARP1BRD4TDP1
SCHEMBL17444764 0.80 TDP1 (0.57) KDM4EPOLBPARP1BRD4TDP1
SCHEMBL13858810 0.79 KDM4E (0.66) KDM4EPOLBPARP1BRD4TDP1
SCHEMBL7122967 0.79 AR (0.77) PARP1LMNAAR
SCHEMBL17444768 0.79 AR (0.64) KDM4EPOLBPARP1BRD4TDP1
SCHEMBL4713932 0.78 SMN1; SMN2 (0.61) KDM4EPOLBPARP1BRD4TDP1
SCHEMBL6783793 0.76 BRD4 (0.53) KDM4EPARP1BRD4TDP1LMNA
SCHEMBL6340069 0.76 BRD4 (0.75) KDM4EPOLBPARP1BRD4TDP1
SCHEMBL18415459 0.75 LMNA (0.66) POLBLMNAALDH1A1HTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9797882-B2 Method of screening for a compound for inhibitory activity of FN14-tweak interaction THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) 2017-10-24 — — US disclosed
US-9797882-B2 Method of screening for a compound for inhibitory activity of FN14-tweak interaction THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) 2017-10-24 — — US disclosed
US-20160146784-A1 COMPOSITIONS AND METHODS OF SCREENING FOR COMPOUNDS THAT MODULATE ACTIVITY AT A TWEAK BINDING SITE ON A CRD OF FN14 THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE 2016-05-26 — — US disclosed
US-20160146784-A1 COMPOSITIONS AND METHODS OF SCREENING FOR COMPOUNDS THAT MODULATE ACTIVITY AT A TWEAK BINDING SITE ON A CRD OF FN14 THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE 2016-05-26 — — US disclosed
US-9238034-B2 FN14 antagonists and therapeutic uses thereof THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) 2016-01-19 — — US disclosed
US-9238034-B2 FN14 antagonists and therapeutic uses thereof THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) 2016-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160146784-A1 COMPOSITIONS AND METHODS OF SCREENING FOR COMPOUNDS THAT MODULATE ACTIVITY AT A TWEAK BINDING SITE ON A CRD OF FN14 FN1, ST14, TNFRSF1A KDM4E 4405/4885POLB 4820/4885PARP1 4176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback